Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
Benoît Misset, Michaël Piagnerelli, Eric A. J. Hoste, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 17, pp. 1590-1600
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Daniele Focosi, Arturo Casadevall, Massimo Franchini, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 17
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Investigational pharmacological agents for the treatment of ARDS
Katyayini Aribindi, Michelle Lim, Satyan Lakshminrusimha, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 3, pp. 243-277
Closed Access | Times Cited: 9
Convalescent plasma and predictors of mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis
Massimo Franchini, Mario Cruciani, Carlo Mengoli, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1514-1522
Closed Access | Times Cited: 8
Deciphering Fc-effector functions against SARS-CoV-2
Guillaume Beaudoin-Bussières, Andrés Finzi
Trends in Microbiology (2024) Vol. 32, Iss. 8, pp. 756-768
Closed Access | Times Cited: 5
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 5
Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial
Visa Nurmi, Richard Mayne, Chanice Knight, et al.
Journal of Infection (2025), pp. 106412-106412
Closed Access
What have we learnt from the COVID-19 pandemic?
Shampa Chatterjee, Amaro Nunes Duarte‐Neto, Marco Cascella, et al.
Elsevier eBooks (2025), pp. 867-892
Closed Access
Coagulation Profile of Convalescent Plasma Donors and Recipients
Hanna Pitkänen, Tuukka Helin, Tamim Khawaja, et al.
Clinical and Applied Thrombosis/Hemostasis (2025) Vol. 31
Open Access
Expansion of SARS-CoV-2 mutations in patient with B-cell lymphoma and rare combination of ACE2, TLR4, DDX58 and IFIH1 variations: A retrospective analysis of the virus-host interplay
Angelina Trifonova, Adelina Yosifova, Atanas Syarov, et al.
Clinical Immunology Communications (2025)
Open Access
The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2
Manish Dhawan, Nanamika Thakur, Manish Sharma, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117936-117936
Closed Access
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome
А. С. Чернов, Maksim V. Rodionov, В. А. Казаков, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: analyses by neutralising antibodies homologous to recipients’ variants
Tuba Khawaja, Mikael Kajova, Iris Levonen, et al.
Infectious Diseases (2024) Vol. 56, Iss. 6, pp. 423-433
Open Access | Times Cited: 3
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Han-Sol Park, Anna Yin, Caelan Barranta, et al.
JCI Insight (2024) Vol. 9, Iss. 8
Open Access | Times Cited: 3
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Hyung Park, Chang Yu, Liise‐anne Pirofski, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 2
The Glycan Ectodomain of SARS-CoV-2 Spike Protein Modulates Cytokine Production and Expression of CD206 Mannose Receptor in PBMC Cultures of Pre-COVID-19 Healthy Subjects
Cristiana Barbati, Carla Bromuro, Silvia Vendetti, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 497-497
Open Access | Times Cited: 2
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2
Anoop Kumar, Prajna Tripathi, Prashant Kumar, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 459-459
Open Access | Times Cited: 2
Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease
Hyunah Yoon, Liise‐anne Pirofski
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 2
Subgroup analyses and heterogeneity of treatment effects in randomized trials: a primer for the clinician
Alexandra B. Spicer, Alexandre Biasi Cavalcanti, Fernando G. Zampieri
Current Opinion in Critical Care (2024) Vol. 30, Iss. 5, pp. 427-438
Closed Access | Times Cited: 2
Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska
Current Opinion in Infectious Diseases (2024) Vol. 37, Iss. 6, pp. 506-517
Closed Access | Times Cited: 2
Effect of SARS-CoV-2 IgG Seroconversion After Convalescent Plasma Transfusion on Hospital Outcomes in COVID-19
Sonal Pannu, Michael H. Cardone, Mohankumar Doraiswamy, et al.
CHEST Critical Care (2024) Vol. 2, Iss. 2, pp. 100048-100048
Open Access | Times Cited: 1
Convalescent plasma: An unexpected new therapeutic option for critically ill COVID-19 patients coming from the past
Massimo Franchini, Arturo Casadevall, Mario Cruciani, et al.
Journal of Clinical Anesthesia (2024) Vol. 94, pp. 111411-111411
Closed Access | Times Cited: 1
Convalescent plasma transfusion for immunocompromised viremic patients with COVID‐19: A retrospective multicenter study
Marjolaine Destremau, H. Chaussade, Victor Hemar, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 4
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top